OBJECTIVE

To study the effectiveness of different treatment methods for patients with the new coronavirus infection COVID-19, complicated by the development of acute arterial thrombosis of various localization.

MATERIAL AND METHODS

We analyzed treatment outcomes in 14 patients with severe course of new coronavirus infection COVID-19 complicated by acute arterial thrombosis. Open thrombectomy under local anesthesia was performed in 4 patients, endovascular recanalization followed by selective catheter-directed thrombolysis with alteplase — in 2 patients. Seven ones underwent systemic transvenous thrombolysis with recombinant human tissue plasminogen activator (alteplase 100 mg). Two patients underwent intravenous infusion of heparin as etiotropic treatment of acute arterial thrombosis.

RESULTS

Mortality rate in patients with arterial thrombosis is much higher (43%) compared to those without vascular complications (mean mortality rate in severe COVID-19 is 21—26%). This fact allows us to consider hypercoagulable state as a predictor of worse prognosis in patients with COVID-19.

CONCLUSION

Various options for systemic and selective catheter-directed thrombolysis are perspective as a promising alternative to open surgical treatment of acute thrombotic conditions associated with COVID-19. Therapeutic measures for acute arterial thrombosis within 48 hours are desirable.